07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

DNX-2401: Phase II started

DNAtrix and Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.) began the open-label, U.S. Phase II CAPTIVE/KEYNOTE-192 trial to evaluate a single intratumoral injection of DNX-2401 followed 7-9 days later by 200 mg IV Keytruda pembrolizumab...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

DNX-2401 regulatory update

EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company said in “the coming weeks” it will begin a Phase II trial evaluating DNX-2401 in combination with Keytruda pembrolizumab...
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Merck, DNAtrix deal

The companies partnered to conduct a Phase II trial combining DNX-2401 from DNAtrix and melanoma drug Keytruda pembrolizumab from Merck to treat recurrent glioblastoma. DNX-2401, a genetically modified oncolytic adenovirus that uses arginine-glycine-aspartic acid (RGD)-binding...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

DNX-2401 regulatory update

FDA granted Orphan Drug designation to DNX-2401 from DNAtrix to treat malignant glioma. DNX-2401 is in Phase I testing for recurrent malignant glioma and recurrent glioblastoma, for which it also has Fast Track designation in...
01:45 , Oct 15, 2014 |  BC Extra  |  Financial News

DNAtrix raises $20M in series B

Cancer play DNAtrix Inc. (Houston, Texas) raised $20 million in an untranched series B round led by new investor Morningside Ventures. Existing investors Mercury Fund, Targeted Technology Fund and unnamed others also participated. Morningside's Reenie...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

DNX-2401 regulatory update

DNAtrix said FDA granted Fast Track designation to DNX-2401 to treat recurrent glioblastoma. DNX-2401 is in Phase I testing for recurrent malignant glioma and recurrent glioblastoma. The genetically modified oncolytic adenovirus uses arginine-glycine-aspartic acid (RGD)-binding...
07:00 , Mar 20, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Beta Cat Pharmaceuticals, CerRx, DNAtrix, Essa Pharma, ProNAi, ProPep Surgical, Cancer Prevention and Research Institute of Texas cancer news

The institute awarded three-year grants totaling up to $63.2 million to six cancer companies based in or relocating to Texas. The institute also awarded $22.9 million for 11 research grants for academic projects and research...
00:39 , Feb 21, 2014 |  BC Extra  |  Politics & Policy

CPRIT awards $63.2 million to cancer companies

The Cancer Prevention and Research Institute of Texas awarded three-year grants totaling up to $63.2 million to six cancer companies based in or relocating to Texas. The institute also awarded $22.9 million for 11 research...